Softwr

Healthcare · head to head

Lunit vs Rx30

Lunit logo

Lunit

Healthcare

FDA cleared and CE marked AI for mammography, tomosynthesis and chest radiography

From
On request
Rated
-
Full reviewWebsite
Rx30 logo

Rx30

Healthcare

Long-established pharmacy management system for independents and small chains

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Lunit the regulatory permission differs by product and by region, and INSIGHT Risk has been filed with the FDA but not cleared, so a buyer who reads a corporate press release rather than the specific clearance for their product and jurisdiction will plan a deployment they cannot legally run.; Rx30 shares ownership with PioneerRx, so the two are not the independent alternatives a shortlist implies, and roadmap priorities are set centrally
  • They diverge on capability: Lunit covers Lunit INSIGHT MMG, Rx30 covers Prescription processing.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Lunit and Rx30 actually diverge.

Attributes where Lunit and Rx30 differ
AttributeLunitRx30
PlatformsWebWindows, Web

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Lunit

  • Lunit INSIGHT MMG
  • Lunit INSIGHT DBT
  • Lunit INSIGHT CXR
  • Volpara density assessment
  • Volpara RiskPathways
  • Volpara dose tracking
  • PACS and mammography workstation integration

Only in Rx30

  • Prescription processing
  • Claims adjudication
  • Inventory and purchasing
  • Point of sale
  • Delivery management
  • Clinical documentation

What people use each for

The jobs each tool is most often brought in to do.

Lunit

  • A national breast screening programme evaluating AI as a second reader to reduce double reading workload where two human readers are currently mandatednot Rx30
  • A breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on DBT specificallynot Rx30
  • An American breast imaging centre needing automated volumetric density assessment to meet patient density notification requirements, which is what Volpara is bought fornot Rx30
  • A tuberculosis or lung screening programme in a high volume, radiologist scarce setting using chest radiography triage to prioritise filmsnot Rx30

Rx30

  • Independent pharmacies and small chains wanting a mature, widely-supported systemnot Lunit
  • Operations relying on a broad set of wholesaler and PBM interfacesnot Lunit
  • Pharmacies with significant front-end retail alongside dispensingnot Lunit
  • Multi-store independents needing consistency across locationsnot Lunit

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Lunit

  • The regulatory permission differs by product and by region, and INSIGHT Risk has been filed with the FDA but not cleared, so a buyer who reads a corporate press release rather than the specific clearance for their product and jurisdiction will plan a deployment they cannot legally run.
  • Detection AI changes recall rates in screening, and the downstream cost of additional diagnostic workup lands on the programme rather than on the software budget, which is the cost most screening business cases omit.
  • Performance is sensitive to the mammography vendor and acquisition protocol, so published results from a Hologic estate do not transfer to a GE or Siemens estate without local validation the buyer must fund.
  • MMG, DBT and CXR are licensed separately and Volpara modules are separate again, so a breast centre wanting detection, density and risk pathways is assembling four line items rather than buying one product.
  • Using AI as a replacement for one of two human readers is a workforce and liability decision that regulators and professional bodies treat differently in each country, so the saving that justifies the purchase may not be permitted where you operate.

Rx30

  • Shares ownership with PioneerRx, so the two are not the independent alternatives a shortlist implies, and roadmap priorities are set centrally
  • The interface shows its age against newer entrants, and this is the most common objection in demonstrations
  • Pricing is not published, and total cost including hardware and interfaces needs to be requested explicitly
  • Windows-centric, with a cloud story less developed than newer competitors
  • US-only, tied to US insurance and regulatory requirements

Pricing, plan by plan

Lunit

On request
  • Lunit INSIGHT$undefined/year
    • Priced per study or per annual examination volume by product
    • MMG, DBT and CXR licensed separately
    • Volpara density and RiskPathways modules quoted separately

Rx30

On request
  • Rx30$undefined/month
    • Prescription processing
    • Claims adjudication
    • Inventory

Which should you pick?

Choose Lunit if

  • You need lunit insight mmg.
  • You also want lunit insight dbt.
Lunit review

Choose Rx30 if

  • You need prescription processing.
  • You work on Windows, Web.
  • You also want claims adjudication.
Rx30 review

Questions people ask

Is Lunit or Rx30 better?
Neither clearly leads. Lunit starts at On request and Rx30 at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Lunit or Rx30?
Lunit starts at On request and Rx30 at On request.
Does Lunit or Rx30 run on more platforms?
Lunit runs on Web. Rx30 runs on Windows, Web.
What is Lunit best used for?
Lunit is most often used for a national breast screening programme evaluating ai as a second reader to reduce double reading workload where two human readers are currently mandated, a breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on dbt specifically, an american breast imaging centre needing automated volumetric density assessment to meet patient density notification requirements, which is what volpara is bought for, a tuberculosis or lung screening programme in a high volume, radiologist scarce setting using chest radiography triage to prioritise films. Of those, a national breast screening programme evaluating ai as a second reader to reduce double reading workload where two human readers are currently mandated and a breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on dbt specifically are not what Rx30 is typically brought in for.
What can Lunit do that Rx30 cannot?
Lunit covers Lunit INSIGHT MMG, Lunit INSIGHT DBT, Lunit INSIGHT CXR, Volpara density assessment. Rx30 covers Prescription processing, Claims adjudication, Inventory and purchasing, Point of sale.

Answered from the vendors’ own pages

Lunit: Is Lunit FDA cleared?

Yes for specific products. INSIGHT MMG, INSIGHT DBT and INSIGHT CXR Triage hold FDA 510(k) clearances. INSIGHT Risk, the five year risk prediction model, has been filed but was not cleared at the time of writing.

Rx30: Is Rx30 the same company as PioneerRx?

Both are owned by RedSail Technologies. They are sold as separate products to overlapping markets, but roadmap decisions sit with one company, which is worth knowing before treating them as independent options.

Lunit: Can Lunit replace a second human reader in screening?

That depends entirely on your jurisdiction and professional body guidance, not on the software. The CE mark permits clinical use; it does not authorise a workforce model.

Rx30: What does it cost?

Not published. Request the total including hardware, interfaces and training rather than the monthly software fee.

Lunit: What did the Volpara acquisition add?

Volumetric breast density measurement, dose tracking and RiskPathways high risk programme management, which are the things American breast centres buy for density notification compliance rather than for detection.

Rx30: Why do pharmacies stay on it?

Installed base maturity. The interfaces to wholesalers, PBMs and hardware are long established, and those are the things that quietly stop a pharmacy working when they break.

Lunit: Is pricing published?

No. It is quoted per study or per annual volume, by product, with on premises and cloud priced differently.

Rx30: How does it compare to PioneerRx?

PioneerRx is more aggressively developed around clinical services. Rx30 has the larger legacy base and broader front-end retail heritage. Same owner, different emphasis.

Rx30: Is it suitable for a small chain?

Yes, and that is one of its stronger cases. Multi-store consistency is better handled here than by the systems aimed purely at single independents.

Share

Related pages

More on Lunit

More on Rx30

Keep looking

Other head to heads